PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT TENAX THERAPEUTICS, INC.Tenax Therapeutics, Inc. • July 8th, 2020 • Services-commercial physical & biological research
THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above as the Initial Exercise Date (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on July 6, 2025 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Tenax Therapeutics, Inc., a Delaware corporation (the “Company”), up to ________ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENT FOR CLASS E AND CLASS F UNITSSecurities Purchase Agreement • July 8th, 2020 • Tenax Therapeutics, Inc. • Services-commercial physical & biological research • New York
This Securities Purchase Agreement for Class E and Class F Units (this “Agreement”) is dated as of July 6, 2020, between Tenax Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 8th, 2020 • Tenax Therapeutics, Inc. • Services-commercial physical & biological research
This Registration Rights Agreement (this “Agreement”) is made and entered into as of July 6, 2020, between Tenax Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
SECURITIES PURCHASE AGREEMENT FOR CLASS C AND CLASS D UNITSSecurities Purchase Agreement • July 8th, 2020 • Tenax Therapeutics, Inc. • Services-commercial physical & biological research • New York
This Securities Purchase Agreement for Class C and Class D Units (this “Agreement”) is dated as of July 6, 2020, between Tenax Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
